MedRx Co., Ltd (TYO:4586)
89.00
-10.00 (-10.10%)
Sep 18, 2025, 3:30 PM JST
MedRx Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 1,667 | 1,977 | 1,720 | 994 | 1,703 | 1,812 | Upgrade |
Cash & Short-Term Investments | 1,667 | 1,977 | 1,720 | 994 | 1,703 | 1,812 | Upgrade |
Cash Growth | -23.04% | 14.94% | 73.04% | -41.63% | -6.02% | 28.51% | Upgrade |
Other Receivables | 15 | 44 | 33 | 15 | 23 | 37 | Upgrade |
Receivables | 15 | 44 | 33 | 15 | 23 | 37 | Upgrade |
Inventory | 17 | 10 | 10 | 8 | 11 | 19 | Upgrade |
Other Current Assets | 52 | 41 | 22 | 70 | 17 | 18 | Upgrade |
Total Current Assets | 1,751 | 2,072 | 1,785 | 1,087 | 1,754 | 1,886 | Upgrade |
Property, Plant & Equipment | 112 | 123 | 181 | 226 | 270 | 328 | Upgrade |
Long-Term Investments | 70 | 79 | 85 | 84 | 83 | 82 | Upgrade |
Other Long-Term Assets | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade |
Total Assets | 1,934 | 2,275 | 2,052 | 1,398 | 2,108 | 2,297 | Upgrade |
Short-Term Debt | - | - | - | - | - | 50 | Upgrade |
Current Income Taxes Payable | 52 | 103 | 98 | 156 | 124 | 71 | Upgrade |
Other Current Liabilities | 10 | 2 | 1 | 2 | 1 | 1 | Upgrade |
Total Current Liabilities | 62 | 105 | 99 | 158 | 125 | 122 | Upgrade |
Long-Term Deferred Tax Liabilities | - | - | 4 | 5 | 5 | 5 | Upgrade |
Other Long-Term Liabilities | - | 2 | 26 | 24 | 23 | 23 | Upgrade |
Total Liabilities | 62 | 107 | 129 | 187 | 153 | 150 | Upgrade |
Common Stock | 252 | 580 | 847 | 227 | 7,803 | 7,376 | Upgrade |
Additional Paid-In Capital | 2,159 | 2,314 | 1,916 | 3,063 | 7,372 | 6,945 | Upgrade |
Retained Earnings | -590 | -787 | -915 | -2,150 | -13,279 | -12,219 | Upgrade |
Comprehensive Income & Other | 51 | 61 | 75 | 71 | 59 | 45 | Upgrade |
Shareholders' Equity | 1,872 | 2,168 | 1,923 | 1,211 | 1,955 | 2,147 | Upgrade |
Total Liabilities & Equity | 1,934 | 2,275 | 2,052 | 1,398 | 2,108 | 2,297 | Upgrade |
Total Debt | - | - | - | - | - | 50 | Upgrade |
Net Cash (Debt) | 1,667 | 1,977 | 1,720 | 994 | 1,703 | 1,762 | Upgrade |
Net Cash Growth | -23.04% | 14.94% | 73.04% | -41.63% | -3.35% | 24.96% | Upgrade |
Net Cash Per Share | 34.81 | 45.48 | 49.46 | 39.19 | 79.74 | 108.46 | Upgrade |
Filing Date Shares Outstanding | 55.5 | 47.5 | 38.48 | 30.7 | 24.6 | 19.7 | Upgrade |
Total Common Shares Outstanding | 53.5 | 47.5 | 38.37 | 28.22 | 24.6 | 19.44 | Upgrade |
Working Capital | 1,689 | 1,967 | 1,686 | 929 | 1,629 | 1,764 | Upgrade |
Book Value Per Share | 34.99 | 45.65 | 50.12 | 42.91 | 79.49 | 110.47 | Upgrade |
Tangible Book Value | 1,872 | 2,168 | 1,923 | 1,211 | 1,955 | 2,147 | Upgrade |
Tangible Book Value Per Share | 34.99 | 45.65 | 50.12 | 42.91 | 79.49 | 110.47 | Upgrade |
Order Backlog | - | - | - | 2 | - | 7.49 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.